Letters to the Editor
Vol. 12 No. 1 (2020): Mediterranean Journal of Hematology and Infectious Diseases, Volume 12, 2020
The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review
COVID-19 in Multiple Myeloma patients
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: August 28, 2020
Accepted: October 21, 2020
Accepted: October 21, 2020
915
Views
299
Downloads
133
HTML
Authors
No abstract, as A letter to the Editor.
Downloads
Download data is not yet available.
Citations
References
1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
2. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017
3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China [published online ahead of print, 2020 Mar 25]. JAMA Oncol. 2020;6(7):1108-1110. doi:10.1001/jamaoncol.2020.0980
4. El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date [published online ahead of print, 2020 Jun 19]. Br J Haematol. 2020;10.1111/bjh.16956. doi:10.1111/bjh.16956
5. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-113. doi:10.3324/haematol.2014.107714
6. Dhakal, B., D’Souza, A., Chhabra, S. et al. Multiple myeloma and COVID-19 Leukemia. (2020) 34:1961–1963 https://doi.org/10.1038/s41375-020-0879-9
7. K Gadó , G Domján, H Hegyesi. ROLE OF INTERLEUKIN-6 IN THE PATHOGENESIS OF MULTIPLE MYELOM. Cell Biology International Volume 24, Issue 4, April 2000, Pages 195-209
8. Pan Luo | Yi Liu | Lin Qiu | Xiulan Liu | Dong Liu | Juan Li .Tocilizumab treatment in COVID?19: A single center experience J Med Virol. 2020,92:814-818.DOI: 10.1002/jmv.25801
9. Giovanni Guaraldi*, Marianna Meschiari*, Alessandro Cozzi-Lepri, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The lancet.com/rheumatology. 2020 , Vol 2,issue 8,E474-E484
10. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) ClinicalTrials.gov Identifier: NCT04320615
11. Hoffman-La Roche. A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA). June 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04409262. Accessed on June 1, 2020.
12. Genentech. A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants with COVID-19 Pneumonia. May 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04372186. Accessed on May 18, 2020.
13. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-1310.
14. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. doi:10.1016/j.autrev.2020.102537
1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
2. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017
3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China [published online ahead of print, 2020 Mar 25]. JAMA Oncol. 2020;6(7):1108-1110. doi:10.1001/jamaoncol.2020.0980
4. El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date [published online ahead of print, 2020 Jun 19]. Br J Haematol. 2020;10.1111/bjh.16956. doi:10.1111/bjh.16956
5. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-113. doi:10.3324/haematol.2014.107714
6. Dhakal, B., D’Souza, A., Chhabra, S. et al. Multiple myeloma and COVID-19 Leukemia. (2020) 34:1961–1963 https://doi.org/10.1038/s41375-020-0879-9
7. K Gadó , G Domján, H Hegyesi. ROLE OF INTERLEUKIN-6 IN THE PATHOGENESIS OF MULTIPLE MYELOM. Cell Biology International Volume 24, Issue 4, April 2000, Pages 195-209
8. Pan Luo | Yi Liu | Lin Qiu | Xiulan Liu | Dong Liu | Juan Li .Tocilizumab treatment in COVID?19: A single center experience J Med Virol. 2020,92:814-818.DOI: 10.1002/jmv.25801
9. Giovanni Guaraldi*, Marianna Meschiari*, Alessandro Cozzi-Lepri, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The lancet.com/rheumatology. 2020 , Vol 2,issue 8,E474-E484
10. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) ClinicalTrials.gov Identifier: NCT04320615
11. Hoffman-La Roche. A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA). June 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04409262. Accessed on June 1, 2020.
12. Genentech. A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants with COVID-19 Pneumonia. May 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04372186. Accessed on May 18, 2020.
13. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-1310.
14. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. doi:10.1016/j.autrev.2020.102537
How to Cite
“The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review: COVID-19 in Multiple Myeloma patients” (2020) Mediterranean Journal of Hematology and Infectious Diseases, 12(1), p. e2020082. doi:10.4084/mjhid.2020.082.
Copyright (c) 2020 Hesham Elsabah, Mahmood B. Aldabt, Ruba Taha, Dina Sameh Soliman, Halima Elomri, Feryal Ibrahim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
